| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- HG-14-10-04
-
- $44.00
-
2026-07-27
- CAS:1356962-34-9
- Purity: 99.76%
- Supply Ability: 10g
|
| | HG-14-10-04 Basic information |
| Product Name: | HG-14-10-04 | | Synonyms: | HG-14-10-04;CS-2526;CS-1175;2-Pyrimidinamine, 5-chloro-4-(1H-indol-3-yl)-N-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-;Anaplastic lymphoma kinase (ALK),HG 14 10 04,Anaplastic lymphoma kinase,ErbB-1,Inhibitor,EGFR,anticancer,HG141004,CD246,inhibit,HER1,Cluster of differentiation 246,Epidermal growth factor receptor,ALK tyrosine kinase receptor;HG-14-10-04, 10 mM in DMSO;5-chloro-4-(1H-indol-3-yl)-N-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidin-2-amine | | CAS: | 1356962-34-9 | | MF: | C29H34ClN7O | | MW: | 532.08 | | EINECS: | | | Product Categories: | | | Mol File: | 1356962-34-9.mol |  |
| | HG-14-10-04 Chemical Properties |
| Boiling point | 761.1±70.0 °C(Predicted) | | density | 1.297±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 13.3 mg/mL (25.00 mM; Need ultrasonic and warming) | | form | Powder | | pka | 14.62±0.30(Predicted) | | color | Light yellow to yellow |
| | HG-14-10-04 Usage And Synthesis |
| Uses | HG-14-10-04 is a potent ALK and mutant EGFR inhibitor with IC50s of 20 nM, 15.6 nM, 22.6 nM and 124.5 nM for ALK, EGFRLR/TM, EGFR19del/TM/CS and EGFRLR/TM/CS, respectively. HG-14-10-04 can be used to research anticancer[1][2]. | | Definition | ChEBI: 5-chloro-4-(1H-indol-3-yl)-N-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2-pyrimidinamine is a member of piperidines. | | IC 50 | EGFRLR/TM: 15.6 nM (IC50); EGFR19del/TM/CS: 22.6 nM (IC50); EGFRLR/TM/CS: 124.5 nM (IC50); ALK: 20 nM (IC50) | | References | [1] U.S. Pat. Appl. Publ. (2012), US 20120028924 A1 [2] Chen H, et al. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem. 2022 May 12;65(9):6840-6858. DOI:10.1021/acs.jmedchem.2c00168 |
| | HG-14-10-04 Preparation Products And Raw materials |
|